Thompson Rahsaan 4

What Happened

• Thompson Rahsaan, Chief Legal & Compliance at Zevra Therapeutics (ZVRA), had 66,667 restricted stock units convert/settle into common shares on June 21, 2026 (reported as derivative exercise/conversion, no cash paid). A related derivative entry shows a zero‑price disposition of 66,667 shares (reported as $0).
• On June 22, 2026, Rahsaan sold 34,557 common shares in open‑market trades at a weighted average price of $12.68, generating proceeds of $438,304. This was a sale (not a purchase) and was executed under a pre‑arranged 10b5‑1 trading plan.

Key Details

• Transaction dates and prices:
  • 2026-06-21: 66,667 RSUs converted/settled to common shares (derivative exercise/conversion, $0).
  • 2026-06-22: 34,557 shares sold in open market at weighted avg $12.68 (range $12.53–$13.19), proceeds $438,304.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes:
  • F1: Each restricted stock unit (RSU) converts to one share of common stock.
  • F2: Sale executed under a 10b5‑1(c) plan adopted 2026‑01‑08.
  • F3: Sale executed in multiple trades; reported price is weighted average; reporting person will provide full trade-by-trade details on request.
  • F4: RSU tranches vested/settled June 21, 2025 and June 21, 2026; remaining tranche vests next anniversary subject to continued service.
• Filing/timeliness: Form 4 filed 2026-06-23 for transactions on 6/21–6/22; this appears to be within the standard 2-business-day Form 4 reporting window.

Context

• The 66,667‑share entry reflects RSU vesting/settlement (no exercise price). A portion of those shares was sold the next day under a pre‑established 10b5‑1 plan; remaining vested shares and future tranche(s) remain subject to the issuer’s vesting schedule. Sales under a 10b5‑1 plan are pre‑scheduled and often reflect routine portfolio or tax‑management actions rather than a contemporaneous view of the company.